Welcome To The 300 Club HUB On AGORACOM
We may not make much money, but we sure have a lot of fun!
Message: Something going on with BIO... Merits more research over weekend ..
Stock is moving up... Note insider buying from a year ago..at twice price of today!
Biosign Technologies Inc. (BIO) |
As of May 26th, 2011 | ||||||
| Filing Date | Transaction Date | Insider Name | Ownership Type | Securities | Nature of transaction | # or value acquired or disposed of | Unit Price |
| Mar 25/11 | Jul 22/10 | D'Amato, Alfonse | Direct Ownership | Common Shares | 10 - Acquisition in the public market | 35,000 | $2.400 USD |
| Mar 25/11 | Jul 22/10 | D'Amato, Alfonse | Direct Ownership | Common Shares | 10 - Acquisition in the public market | 20,000 | $2.400 USD |
| Mar 25/11 | Jul 22/10 | D'Amato, Alfonse | Direct Ownership | Common Shares | 10 - Acquisition in the public market | 10,000 | $2.030 USD |
| Mar 25/11 | Jul 21/10 | D'Amato, Alfonse | Direct Ownership | Common Shares | 10 - Acquisition in the public market | 100,000 | $1.220 USD |
| Mar 25/11 | Jul 21/10 | D'Amato, Alfonse | Direct Ownership | Common Shares | 10 - Acquisition in the public market | 15,000 | $1.990 USD |
| Mar 25/11 | Jul 20/10 | D'Amato, Alfonse | Direct Ownership | Common Shares | 10 - Acquisition in the public market | 10,000 | $1.800 USD |
| Mar 25/11 | Jul 15/10 | D'Amato, Alfonse | Direct Ownership | Common Shares | 10 - Acquisition in the public market | 10,000 | $1.220 USD |
| Mar 25/11 | Jul 15/10 | D'Amato, Alfonse | Direct Ownership | Common Shares | 10 - Acquisition in the public market | 10,000 | $1.200 USD |
| Mar 25/11 | Jul 22/10 | D'Amato, Alfonse | Direct Ownership | Common Shares | 00 - Opening Balance-Initial SEDI Report | ||
| Mar 25/11 | Jun 30/10 | D'Amato, Alfonse | Direct Ownership | Warrants | 16 - Acquisition under a prospectus exemption | 38,462 | $0.650 USD |
 - Amended Filing |
Had this stock on watch list and accumulated some interesting Tid Bits a few weeks ago from SH which I'll post below....
After reading up on the BIO UFIT 20, it seems to focus on 3 points.
- Blood Pressure
- Heart Rate
- Glucose ( Sugar Level )
Remember we are asking someone to replace their test strips and finger prick method of measuring blood glucose based on a post hoc correlation via the sound of blood rushing through your veins? Now, we have to determine if BIO has a real time clinical trial to determine the accuracy?
For me the most amazing part is there are millions on diabetics out there that have to test their sugar levels through pricking their fingers. If it can now be done without the testing the blood, millions of people would prefer to do it that way I'm sure.
Would be great to know the cost??
>International Organization for Standardization (ISO). According to ISO 15197 Blood glucose meters must provide results that are within 20% of a laboratory standard 95% of the time (for concentrations about 75 mg/dL, absolute levels are used for lower concentrations).”...............
What is the Biosigns claim regarding the accuracy of the UFIT in measuring blood glucose in a non invasive manner as compared to a lab blood test? Inquiring minds needs to know...
DELL IS A GLOBAL LEADER RELATIVE TO ONLINE HEALTHCARE AND DynamiCARE solutions for a healthy world
2)BIO has an ISO accreditation under ISO 13485:2003 which covers medical devices – “ISO 13485:2003 specifies requirements for a quality management system where an organization needs to demonstrate its ability to provide medical devices and related services that consistently meet customer requirements and regulatory requirements applicable to medical devices and related services".............I do not know if meeting #2 above means you have met the requirements of #1..........anybody know?
Together they are the Dynamic Duo at Biosigns side.
DynamiCAREPresidentPatrick Dressler stated: "We were very impressedwith theperformance andease of use of the UFIT® TEN-20 blood pressure&blood glucose meterthat was demonstrated to us by Biosign sinceJune2010 and to the AnnualMeeting of the European MedicalDeviceDistributors in December 2010. Uponfurther negotiations withBiosign,we concluded that our financialresources would be betterusedmarketing this remarkable product ratherthan expending themonexclusivity payments. We expect UFIT to have alarge impact ontheEuropean chronic disease management industry in thecoming monthsandwe look forward to a fruitful business relationship withBiosign."
Watch This Video:> http://www.dynamicare.ch/en/myufit/biosign-video.html
Always do your own dd
Get The:
Point>
http://www.ncbi.nlm.nih.gov/pubmed?term="Gutman S"[Author]">Gutman S, Bernhardt P, Pinkos A, Moxey-Mims M, Knott T, Cooper J.
Center for Devices and Radiologic Health, Rockville, Maryland 20855, USA.
Abstract
The Medical Device Amendments of 1976 to the Federal Food, Drug, and Cosmetic Act (the Act) established three regulatory classes for medical devices. Section 513 of the Act specifies three classes based upon the degree of control and Food and Drug Administration (FDA) oversight that is necessary to assure that the various types of devices are safe and effective. High-risk devices are placed into the most regulated device class, Class III. Under Section 515 of the Act, all devices placed in Class III are subject to premarket approval (PMA) requirements. PMA by FDA is the required process of scientific review to ensure the safety and effectiveness of Class III devices. Advisory panel review is required of virtually all original submissions. Manufacturing facilities of devices requiring PMA approval are also subject to preapproval inspection to assure data integrity and compliance with good manufacturing practices. An approved PMA is granted for marketing a particular medical device for a particular intended use. FDA considers noninvasive and minimally invasive glucose devices that are intended to measure, monitor, or predict blood glucose levels in diabetics to be high-risk medical devices. These devices will have a significant potential impact on the medical care of people with diabetes. The technology offers potential improvements in the quality of life, enhanced blood glucose control through increased frequency of testing, or access to testing, in a broader range of patients. However, the technology is not yet well understood, and the information obtained from these devices is often different from the information that has been the traditional base for the management of diabetes. As a result, FDA requires both analytical and clinical studies to support the intended claims for these new devices.
New Message
Please
login
to post a reply